Zydus Lifesciences Limited
ZYDUSLIFE
Clasificación en acciones
#1758
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Precio por acción
$12.04
Capitalización bursátil
$12.01B
Cambio (1 día)
-2.15%
Cambio (1 año)
6.00%
País
IN
Comercio Zydus Lifesciences Limited (ZYDUSLIFE)
Categoría
Healthcare
Ingresos de Zydus Lifesciences Limited (ZYDUSLIFE)
Ingresos en Jun 2026 TTM: $3.16B
Según los últimos informes financieros de Zydus Lifesciences Limited, los ingresos actuales de la empresa (TTM) son $3.16B. En 2025, la empresa obtuvo unos ingresos de $2.72B un aumento con respecto a los ingresos del año 2024, que fueron de $2.34B. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Zydus Lifesciences Limited desde 2004 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $3.16B | 16.11% |
| 2025 | $2.72B | 15.92% |
| 2024 | $2.34B | 11.77% |
| 2023 | $2.10B | 5.37% |
| 2022 | $1.99B | 1.17% |
| 2021 | $1.97B | 4.00% |
| 2020 | $1.89B | -0.21% |
| 2019 | $1.90B | 3.69% |
| 2018 | $1.83B | 26.46% |
| 2017 | $1.45B | 1.62% |
| 2016 | $1.42B | 2.63% |
| 2015 | $1.39B | 15.37% |
| 2014 | $1.20B | 3.47% |
| 2013 | $1.16B | 15.71% |
| 2012 | $1.00B | 0.20% |
| 2011 | $1.00B | 22.04% |
| 2010 | $820.89M | 45.59% |
| 2009 | $563.82M | -0.43% |
| 2008 | $566.27M | 37.48% |
| 2007 | $411.90M | 26.93% |
| 2006 | $324.50M | 14.00% |
| 2005 | $284.66M | 3.30% |
| 2004 | $275.56M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 109.54% |
IN
|
